NCT05433181撤回1 期
A Phase 1/2, Randomized Double-blind Placebo-Controlled Trial to Test the Safety and Antiviral Activity of ACE2 Chewing Gum on SARS-CoV-2 Viral Load (COVID 19)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Evaluate the safety and tolerability of CTB-ACE2 chewing gum.
研究概览
简要总结
A randomized double-blind, placebo controlled clinical trial of the safety, tolerability, and antiviral activity of angiotensin-converting enzyme 2 (ACE2) chewing gum over a 3-day period in non-hospitalized subjects with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able and willing to provide informed consent prior to initiation of study procedures.
- •Stated willingness to comply with all study procedures and availability for the duration of the study.
- •Male or female, aged 18 years to 65 years.
- •Had a positive PCR or antigen test for SARS-CoV-2 within 72 hours of enrollment.
- •In the opinion of the investigator, has the ability to comply with study procedures including chewing the study products (gum).
- •Stated willingness to refrain from brushing, eating or using any oral health care products, including mouth rinses at least one hour prior to first saliva sample.
- •Stated willingness to abstain from eating mints or other chewing gums during the duration of the study.
- •Stated willingness to abstain from using mouth rinse/gargling solutions at the time of enrollment and for the duration of the study.
- •Stated willingness to use an acceptable method of birth control throughout duration of the study. Acceptable methods include hormonal contraceptives, barrier methods, abstinence, or other effective methods approved by the PI.
- •Stated ability and willingness to store saliva samples at approximately 40° F for 3 days.
排除标准
- •Individuals receiving antiviral medications that are thought to be active against SARS-CoV-2 in the opinion of the investigator.
- •Individuals receiving oral or injectable antimicrobial medications (antibacterial, antiviral, antibiotics, including hydroxychloroquine) at time of enrollment.
- •Currently undergoing cancer treatment.
- •Pregnant or breastfeeding women.
- •Participation in any other clinical trial within the past 14 days that used an investigational drug product.
- •Admitted to the hospital or other medical facility or in the opinion of the investigator expected to require admission to a medical facility for the duration of the study.
- •Taking chronic immunosuppressive medications at time of enrollment, defined as immunomodulatory agents or a prednisolone dose greater than 10 mg a day.
- •Uncontrolled hypertension, defined as ≥160 mmHg systolic or ≥100 mmHg diastolic.
- •Allergy/hypersensitivity to lettuce, gelatin (plant based), stevia, or unwillingness to consume genetically modified plant material.
研究组 & 干预措施
Placebo Chewing Gum
Placebo Comparator
干预措施: Placebo Chewing Gum (Other)
ACE2 Chewing Gum
Experimental
干预措施: ACE2 Chewing Gum (Drug)
结局指标
主要结局
Evaluate the safety and tolerability of CTB-ACE2 chewing gum.
时间窗: At time of consent through Day 28
The safety and tolerability in COVID 19+ adult individuals as measured by frequency of solicited adverse events (AEs).
次要结局
- Test the antiviral activity of ACE2 chewing gum on reducing SARS-CoV-2 viral load in the oral cavity of COVID-19+ individuals via authorized PCR.(Days 1-4)
- Evaluate the Symptom score of documented SARS-CoV-2 infection relative to treatment group (CTB-ACE2 chewing gum/placebo).(Days 1-4)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 PatientsMild to Moderate COVID-19NCT05941793Oneness Biotech Co., Ltd.135
已完成
2 期
Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy AdultsMarburg Virus DiseaseNCT05817422Albert B. Sabin Vaccine Institute126
已完成
2 期
Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy AdultsEbola Sudan Virus DiseaseNCT06036602Albert B. Sabin Vaccine Institute125
进行中（未招募）
2 期
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy AdultsMarburg Virus DiseaseNCT06620003Albert B. Sabin Vaccine Institute200
已完成
2 期
ANAVEX2-73 Study in Parkinson's Disease DementiaParkinsons Disease With DementiaNCT03774459Anavex Life Sciences Corp.132